Mildronate, a regulator of energy metabolism, reduces atherosclerosis in apoE/LDLR mice

Pharmacology

Volumn 83, Issue 5, 2009, Pages 287-293

  Vilskersts, Reinis ^a,b   Liepinsh, Edgars ^a,b   Mateuszuk, Lukasz ^c   Grinberga, Solveiga ^b   Kalvinsh, Ivars ^b   Chlopicki, Stefan ^c   Dambrova, Maija ^b  

^a UNIVERSITY OF LATVIA   (Latvia)

^b LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

ApoE LDLR mice; Atherosclerosis; Energy metabolism; L Carnitine; Mildronate

Indexed keywords

APOLIPOPROTEIN E; CARNITINE; CHOLESTEROL; GAMMA BUTYROBETAINE DIOXYGENASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MILDRONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; AORTA WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DESCENDING AORTA; ENERGY METABOLISM; FEMALE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE LEVEL;

ANIMALS; AORTA; ATHEROSCLEROSIS; BETAINE; CARDIOVASCULAR AGENTS; CARNITINE; ENERGY METABOLISM; FEMALE; LIPIDS; MALE; METHYLHYDRAZINES; MICE; MICE, KNOCKOUT; RATS; RATS, WISTAR;

EID: 62949240070     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210015     Document Type: Article

References (35)

1. Barish GD: Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity. J Nutr 2006;136: 690-694.
2. Lusis AJ: Atherosclerosis. Nature 2000;407: 233-241.
3. Wang W, Lopaschuk GD: Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Expert Rev Cardiovasc Ther 2007;5:1123-1134.
4. Aronson D, Rayfield EJ: How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002;1:1.
5. Shankar SS, Mirzamohammadi B, Walsh JP, Steinberg HO: L -carnitine may attenuate free fatty acid-induced endothelial dysfunction. Ann NY Acad Sci 2004;1033:189-197.
6. Edirisinghe I, McCormick HK, Kappagoda CT: Effect of fatty acids on endothelium-dependent relaxation in the rabbit aorta. Clin Sci (Lond) 2006;111:145-151.
7. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85: 1093-1129.
8. Dagher Z, Ruderman N, Tornheim K, Ido Y: Acute regulation of fatty acid oxidation and AMP-activated protein kinase in human umbilical vein endothelial cells. Circ Res 2001;88:1276-1282.
9. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C: Therapeutic effects of L -carnitine and propionyl- L -carnitine on cardiovascular diseases: a review. Ann NY Acad Sci 2004;1033:79-91.
10. Mingrone G: Carnitine in type 2 diabetes. Ann NY Acad Sci 2004;1033:99-107.
11. Broderick TL, Christos SC, Wolf BA, DiDomenico D, Shug AL, Paulson DJ: Fatty acid oxidation and cardiac function in the sodium pivalate model of secondary carnitine deficiency. Metabolism 1995;44:499-505.
12. Liepinsh E, Vilskersts R, Skapare E, Svalbe B, Kuka J, Cirule H, Pugovics O, Kalvinsh I, Dambrova M: Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart. Life Sci 2008;83:613-619.
13. Simkhovich BZ, Shutenko ZV, Meirena DV, Khagi KB, Mezapuke RJ, Molodchina TN, Kalvins IJ, Lukevics E: 3-(2,2,2-Trimethyl-hydrazinium)propionate (THP): a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 1988;37:195-202.
14. Kuwajima M, Harashima H, Hayashi M, Ise S, Sei M, Lu K, Kiwada H, Sugiyama Y, Shima K: Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2,2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. J Pharmacol Exp Ther 1999;289:93-102.
15. Hayashi Y, Muranaka Y, Kirimoto T, Asaka N, Miyake H, Matsuura N: Effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on tissue carnitine and lipid levels in rats. Biol Pharm Bull 2000;23:770-773.
16. Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M: Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol 2006;48:314-319.
17. Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Stieger B, Krahenbuhl S: Development and characterization of an animal model of carnitine deficiency. Eur J Biochem 2001;268:1876-1887.
18. Dambrova M, Liepinsh E, Kalvinsh I: Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 2002;12:275-279.
19. Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA: Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting he-modynamics. J Cardiovasc Pharmacol 2006;47:493-499.
20. Aoyagi T, Sugiura S, Eto Y, Yonekura K, Matsumoto A, Yokoyama I, Kobayakawa N, Omata M, Kirimoto T, Hayashi Y, Momomura S: Inhibition of carnitine synthesis protects against left ventricular dysfunction in rats with myocardial ischemia. J Cardiovasc Pharmacol 1997;30:468-474.
21. Hayashi Y, Tajima K, Kirimoto T, Miyake H, Matsuura N: Cardioprotective effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on cardiac dysfunction induced by ischemia/reperfusion in isolated rat hearts. Pharmacology 2000;61:238-243.
22. Rupp H, Zarain-Herzberg A, Maisch B: The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002;27:621-636.
23. Sjakste N, Kalvinsh I: Mildronate: an an-tiischemic drug with multiple indications. Pharmacologyonline 2006;1:1-18.
24. Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, Chlopicki S, Korbut R: Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2005;56:627-635.
25. Dambrova M, Cirule H, Svalbe B, Zvejniece L, Pugovichs O, Zorenko T, Kalvinsh I, Liepinsh E, Belozertseva I: Effect of inhibiting carnitine biosynthesis on male rat sexual performa nce. Physiol Behav 2008;95:341-347.
26. Culic O, Gruwel ML, Schrader J: Energy turnover of vascular endothelial cells. Am J Physiol 1997;273:C205-C213.
27. Asaka N, Muranaka Y, Kirimoto T, Miyake H: Cardioprotective profile of MET-88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts. Fundam Clin Pharmacol 1998;12: 158-163.
28. Bell FP: Carnitine ester hydrolysis in arteries from normal and cholesterol-fed rabbits and the effects of carnitine esters on arterial microsomal ACAT. Comp Biochem Physiol B 1984;79:125-128.
29. Dainty IA, Bigaud M, McGrath JC, Spedding M: Interactions of palmitoyl carnitine with the endothelium in rat aorta. Br J Pharmacol 1990;100:241-246.
30. Taki H, Muraki K, Imaizumi Y, Watanabe M: Mechanisms of the palmitoylcarnitine-induced response in vascular endothelial cells. Pf lugers Arch 1999;438: 463-469.
31. Sjakste N, Gutcaits A, Kalvinsh I: Mildronate: an antiischemic drug for neurological indications. CNS Drug Rev 2005;11:151-168.
32. Akahira M, Hara A, Abiko Y: Effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on myocardial derangements induced by hydrogen peroxide in the isolated perfused rat heart. Fundam Clin Pharmacol 1997;11:356-364.
33. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N: L -carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res 2001; 44:235-242.
34. Chang C, Dong R, Miyazaki A, Sakashita N, Zhang Y, Liu J, Guo M, Li BL, Chang TY: Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 2006;38:151-156.
35. Chiwata T, Aragane K, Fujinami K, Kojima K, Ishibashi S, Yamada N, Kusunoki J: Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Br J Pharmacol 2001;133:1005-1012.